Obituaries   |   Area Deaths   |   Crime Watch   |   Celebrations   |   Real Estate Transfers   |   Permits

NEOMED Pharmacy Alumni Perform at National Level on Licensure Exams

UPublish story by Heather Bing

The College of Pharmacy at Northeast Ohio Medical University (NEOMED) is pleased to announce the exceptional performance of its Class of 2012 graduates on the North American Pharmacist Licensure Examination (NAPLEX) and Multistate Pharmacy Jurisprudence Examination (MPJE).

Graduates must pass the national board exams to become licensed pharmacists. The recent graduating class of NEOMED pharmacists achieved a first-time pass rate of 97 percent on the NAPLEX, a 98 percent first-time pass rate on the in-state MPJE and a 100 percent first-time pass rate on the out-of-state MPJE. At the national level, the NAPLEX first-time pass rate averaged at 97 percent and the MPJE first-time pass rate averaged at 94 percent.

"The licensure exam results for our second class of pharmacists are outstanding; they have performed at or above the level of their national peers, which speaks to the caliber of their education and experiences and implies their impact and achievements in practice are soon to follow," said Richard J. Kasmer, Pharm.D., J.D., interim dean for the College of Pharmacy. "We are very proud of this second graduating class. Their licensure exam results indicate a strong, continuing theme of success among our graduates.”

Results were released by the National Association of Boards of Pharmacy and reflect examinations taken between May 1 and Aug. 31 by 60 of the College of Pharmacy’s 66 graduates for the NAPLEX and 62 of the 66 graduates for the MPJE. Of the 62 graduates who took the MPJE, 47 took the in-state exam and 15 took the out-of-state exam.


This story was provided by an individual or organization for use on the Ohio.com community site, http://www.ohio.com/upublish. We do not endorse and cannot guarantee the accuracy of this posting, though we do reject announcements with inappropriate content. You can read our full user agreement here.


Story tools

Email  Email   Print  Print   Reprint  Reprint   Popular  Most Popular   Subscribe  Subscribe

Share this story